DOCSLIB.ORG

TPA Collaborative Practice Agreement Guidance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TPA Collaborative Practice Agreement Guidance TPA Collaborative Practice Agreement Guidance Table of Contents 1. Definition of Clinical Pharmacy Practice within a Collaborative Practice Agreement (CPA) A. Definition of Clinical Pharmacy Services B. Scope of Practice C. Establishment of Competencies D. Professional Practice Evaluations 2. Patient Care Delivery by a Pharmacist within a CPA A. Comprehensive Medication Management (CMM) B. Modalities of Comprehensive Medication Management C. Methods of Referral D. Involvement of Trainees 3. Business Models by Pharmacist within a CPA A. Income Generating B. Cost Avoidance 4. Outcome Evaluation of Pharmacy Services within a CPA A. Documentation B. Evaluation of Outcomes TPA Collaborative Practice Agreement Guidance Introduction Clinical Pharmacists play an important role in the provision of comprehensive medication management to Tennesseans. Clinical Pharmacists have a unique role and skill set to identify medication management issues thereby promoting the safe and effective use of medications. This document has been created by the Tennessee Pharmacists Association in an effort to facilitate the initiation of collaborative practice agreements between clinical pharmacists and prescribing clinicians with a focus on caring for patients receiving complex medication regimens. 1. Definition of Clinical Pharmacy Practice within a CPA The American College of Clinical Pharmacy (ACCP) defines clinical pharmacy as the area of pharmacy concerned with the science and practice of rational medication use. Clinical pharmacists have obtained advanced training so that they possess the qualifications necessary to provide team-based, direct patient care. With the creation of the collaborative practice agreement (CPA), clinical pharmacists may advance to providers with expertise in comprehensive medication management (CMM). This advancement should focus on improved clinical patient outcomes associated with various chronic disease states in the ambulatory care setting. A. Definition of Clinical Pharmacy Services Clinical pharmacists in a CPA work with a defined scope of practice (SOP) to independently perform CMM for patients. The clinical pharmacist with a defined SOP within a CPA provides direct patient care and functions at the highest level of clinical practice. They work with a high level of autonomy and independent decision- making within the parameters of their SOP as defined by the individual facility or provider with whom the CPA is established. Pharmacists working in this capacity can initiate, modify or discontinue medications, order and review laboratory tests, make referrals to other medical providers and serve as a conduit to increased specialized pharmacotherapy care between patients’ normal primary care provider (PCP) appointments. Clinical pharmacists should focus on providing CMM within a CPA and address the totality of the patient’s pharmacotherapy needs. Common clinical pharmacy comprehensive medication services include but are not limited to: 1. Anticoagulation 2. Diabetes 3. Hypertension 4. Hyperlipidemia 5. Pain Management 6. Heart Failure 7. Asthma/COPD 8. Smoking Cessation TPA Collaborative Practice Agreement Guidance B. Initiation of a Scope of Practice for the Clinical Pharmacist practicing within a CPA The initiation of scope, credentialing, and professional practice requirements for the clinical pharmacist practicing within a CPA should be established and individualized based on the health care site and/or the provider establishing the CPA. This process should follow site and area-specific credentialing practices. The SOP should allow for initiation, modification, discontinuation of medications and necessary monitoring authorities for the provision of CMM. (Attachment A-Scope of Practice/CPA Examples) C. Establishment of Competencies All clinical pharmacists initiating a SOP within a CPA should have appropriate competency assessment of the critical duties outlined in their scope. This ensures the provider or the facility with whom the CPA is entered into can determine the clinical pharmacist's readiness and abilities for their position. There are a variety of ways to determine the individual pharmacist’s competency for establishing scope of practice, including an evaluation of past education and experience. The evaluation of competency may include one or more of the following items: Completion of a PGY1 Pharmacy Practice Residency Completion of a PGY2 Specialty Pharmacy Residency, in ambulatory care or areas with emphasis in primary care disease states/conditions Completion of a Post-Graduate Fellowship with an emphasis in primary care disease states/conditions Board Certification in Ambulatory Care or Pharmacotherapy (BCACP or BCPS) Experience providing direct patient care under a scope of practice (or collaborative practice agreement) in the primary care setting Evaluation through a Core Competency Assessment Form developed by the individual provider or facility with whom the CPA is being initiated (See Attachment B). Completion of a mentorship with a practitioner in a similar practice D. Professional Practice Evaluations The Professional Practice Evaluation (PPE) is an organized process carried out by an individual health care practitioner or select committee of healthcare professionals to evaluate the performance of other professionals in an ongoing manner. The PPE process of the pharmacist operating within a CPA should become an important part of quality assurance in the future for any practice site where a CPA is initiated. The PPE program should include both initial, focused professional practice evaluations (FPPE) and ongoing professional practice evaluations (OPPE), as indicated by defined triggering events. When evaluating the quality of care provided by clinical pharmacists practicing within a CPA, it is important that the PPE program evaluates the types of patients and spectrum of diseases and conditions seen by the clinical pharmacist. In recent years the Joint Commission has developed guidelines regarding TPA Collaborative Practice Agreement Guidance the use of PPEs. Many payers and other accrediting bodies have also mandated PPE, which has led to its use by many health systems as their primary mechanism for quality improvement. Typically directed at the observation of a particular medical staff member, the Joint Commission has developed six core areas of measurement: patient care medical/clinical knowledge practice-based learning and improvement interpersonal and communication skills professionalism systems-based practice The Joint Commission recommends that the PPE process be developed and overseen by the health system or the individual provider with whom the pharmacist has initiated a CPA. Examples can be seen in Attachment C. 2. Patient Care Delivery by a Pharmacist within a CPA A. Comprehensive Medication Management Comprehensive Medication Management (CMM) encompasses the medication management of patients with chronic disease states. At a minimum, the clinical pharmacist should have a SOP to provide medication management for the following “core” disease states: anticoagulation, hypertension, hyperlipidemia, and diabetes. The goal is for the clinical pharmacist to expand his or her CMM SOP to include not only the “core” disease states, but, also, any additional chronic disease states, including but not limited to pain, heart failure, mental health, hepatitis C, hypothyroidism, gout, COPD, contraception, asthma, smoking cessation, and osteoporosis. B. Modalities of Comprehensive Medication Management i. Face to Face A traditional direct patient care visit is conducted in the outpatient setting between a pharmacist and a patient. Face-to-face visits are best suited for new patients, patients requiring multiple complex interventions, patients with hearing or cognitive impairments, or patients who are difficult to reach by phone. ii. Non Face-to-Face A non-traditional direct patient care visit can be conducted over the telephone or by other electronic medium between a pharmacist and a patient. Various forms of non-telephonic visits currently exist and continue to be developed. Examples include commercial video conferencing programs (Skype™, FaceTime, etc.) as well as telemedicine programs designed for specific healthcare system use. Pharmacist-driven telephonic clinics contribute to the management of the complex patient who requires frequent medication adjustments, has consistent phone access, and prefers to limit trips to the medical center. Non face-to-face care is a core component of CMM; therefore, thorough documentation remains vital. TPA Collaborative Practice Agreement Guidance C. Methods of Referral Clear and standardized processes for referral of patients to the clinical pharmacist should be established within the CPA. The most important thing to ensure is that the appropriate patient is referred to the clinical pharmacist for management. The infrastructure should always exist for the clinical pharmacist to refer to higher levels of care as needed. The referral method should be simple and avoid causing extra work for the referring provider or the clinical pharmacist. For all patients managed by the clinical pharmacist, it is important to develop guidance for discharge in case of frequently missed visits, failure to follow instructions, or continued demonstration of poor medication adherence despite intensive efforts by the clinical pharmacist. Continuity of care with the primary care provider should always be consistent. Referrals for care from providers or team members to the
Load more

Recommended publications
  • Clinical Pharmacy Specialist
    SAMPLE JOB DESCRIPTION Clinical Pharmacist Specialist I. JOB SUMMARY The Clinical Pharmacist Specialists are responsible and accountable for the provision of safe, effective, and prompt medication therapy. Through various assignments within the department, they provide support of centralized and decentralized medication-use systems as well as deliver optimal medication therapy to patients with a broad range of disease states. Clinical Pharmacist Specialists proficiently provide direct patient-centered care and integrated pharmacy operational services in a decentralized practice setting with physicians, nurses, and other hospital personnel. These clinicians are aligned with target interdisciplinary programs and specialty services to deliver medication therapy management within specialty patient care services and to ensure pharmaceutical care programs are appropriately integrated throughout the institution. In these clinical roles, Clinical Pharmacist Specialists participate in all necessary aspects of the medication-use system while providing comprehensive and individualized pharmaceutical care to the patients in their assigned areas. Pharmaceutical care services include but are not limited to assessing patient needs, incorporating age and disease specific characteristics into drug therapy and patient education, adjusting care according to patient response, and providing clinical interventions to detect, mitigate, and prevent medication adverse events. Clinical Pharmacist Specialists serve as departmental resources and liaisons to other
    [Show full text]
  • Patient Safety Clinical Pharmacy Collaborative (PSPC) Guidebook
    GUIDEBOOK Planning and Implementing a Successful Collaborative in a Rural Area How the Eastern Virginia Medical School (EVMS) Patient Safety and Clinical Pharmacy Services Collaborative is changing Pharmacy Services in the Eastern Virginia ACKNOWLEDGEMENTS Thank you to the many people who contributed to this document. We acknowledge the Eastern Virginia Medical School Patient Safety and Clinical Pharmacy Services Collaborative members who initiated the development of this document. Thank you to the participant organizations’ leadership members who consistently supported these efforts. The following individuals provided extensive time, effort and dedication to the development of this document: Judy Wessell Judy A. Wessell MSN, APRN, BC, ACRN, AACRN, AAHIVS. Ms. Wessell has been an HIV Nurse Practitioner for 13 years and a Registered Nurse for greater than 36 years. She received her diploma of Nursing from the Newport Hospital School of Nursing in Newport, RI, her BSN and MSN at Old Dominion University, Norfolk, VA. Ms. Wessell is currently the Nurse Practitioner Supervisor at the Eastern Virginia Medical School (EVMS), Center for Care of Immune Deficiency (C3ID), Infectious Disease Clinic. She is an HIV Health Educator with the EVMS AIDS Resource and Consultation Center, providing professional and community educational programs. She is a member of the quality improvement committee and a member of the EVMS Patient Safety and Clinical Pharmacy Collaborative. Tanya Kearney Tanya K. Kearney, MPA, has eight years of experience as Director for the AIDS Resource Center at Eastern Virginia Medical School. She works with health care providers, community- based AIDS service organizations, government agencies, professional associations and academic and community health care providers, to offer multidisciplinary educational programs on HIV/AIDS and other related topics.
    [Show full text]
  • Clinical Pharmacy in Family Practice
    Clinical Pharmacy in Family Practice John P. Geyman, MD One of the innovative directions in family prac­ services has been high.2 Similar collaborative ef­ tice during the last several years has been the in­ forts between family practice and clinical phar­ troduction of clinical pharmacists into some teach­ macy have been reported in other medical schools, ing and community practices. This is not surpris­ such as the Medical University of South Carolina2; ing in view of recent changes in pharmacy educa­ and in community hospital based family practice tion and practice, which have expanded the clini­ residencies, such as Family Medicine Spokane in cal training of clinical pharmacists and increased Washington State.4 the range of services which they provide. There With regard to community practices, several are growing numbers of clinical pharmacists in questions are immediately raised concerning this teaching hospitals, outpatient clinics, mental kind of interdisciplinary practice, including ethical health centers, and other institutional settings.1 and economic issues, if dispensing of drugs is to be Although the entry of clinical pharmacists into the carried out; also, logistic and procedural ques­ relatively smaller group settings of family practice tions; cost-benefit questions; and questions re­ is still an early trend, the experience to date in garding satisfaction of patients, physicians, and both teaching and community practice settings is pharmacists. Of particular interest in terms of how extremely positive. these questions have been resolved in one practice In this issue of The Journal, Love and his col­ is the report of Davis and his colleagues of their leagues describe the role and contributions of a experience since 1976 in a rural-suburban family clinical pharmacist in the university based family practice in Lexington, South Carolina.5 This prac­ practice residency program at the University of tice includes two family physicians and one clin­ Kentucky.
    [Show full text]
  • HRSA's Patient Safety and Clinical Pharmacy Services Collaborative
    HRSA’s Patient Safety and Clinical Pharmacy Services Collaborative (PSPC) Krista M. Pedley, PharmD, MS Collaborative Improvement Advisor Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA) Healthcare Systems Bureau (HSB) Office of Pharmacy Affairs (OPA) 1 What is the Collaborative? • Improve patient safety, improve health outcomes, through integration of clinical pharmacy services • Rapid improvement method – uses IHI model • Leading practices come from the field • Principle of “All Teach, All Learn” 2 How Does the PSPC Create Improvements? • 16 mon th rapid l earni ng mod el • Focused on improving health outcomes • Led by an expert faculty and national leaders • Creates community of learning • Learning Sessions and Action Periods are venues for change • Improvements are tracked and shared for mutual benefit 3 Institute of Medicine Findings on PtitSftPatient Safety and dE Errors • Medication Errors are Most Common • Injure 1.5 Million People Annually • Cost Billions Annually “…for every dollar spent on ambulatory medications, another dollar is spent to treat new health problems caused bhby the me dication. ” 4 HRSA’s Commitment • StSupport programs to provide th e b est and saf est care in the Nation • Take previously supported Collaboratives with documented improvements to the next level • Going beyond one disease at a time to full patient-centered care 5 Patient Safety and Clinical Pharmacy Services Collaborative (PSPC): Aim “Committed to saving and enhancing thousands of lives a year by achieving optimal health outcomes and eliminating adverse drug events through increased clinical pharmacy services for the patients we serve.” 6 PSPC Performance Goals 1. All T eams will h ave a CPS process.
    [Show full text]
  • ASHP Statement on Pharmaceutical Care
    Medication Therapy and Patient Care: Organization and Delivery of Services–Statements 331 ASHP Statement on Pharmaceutical Care The purpose of this statement is to assist pharmacists in under- Care. Central to the concept of care is caring, a personal standing pharmaceutical care. Such understanding must pre- concern for the well-being of another person. Overall cede efforts to implement pharmaceutical care, which ASHP patient care consists of integrated domains of care including believes merit the highest priority in all practice settings. (among others) medical care, nursing care, and pharmaceu- Possibly the earliest published use of the term pharma- tical care. Health professionals in each of these disciplines ceutical care was by Brodie in the context of thoughts about possess unique expertise and must cooperate in the patient’s drug use control and medication-related services.1,2 It is a overall care. At times, they share in the execution of the various term that has been widely used and a concept about which types of care (including pharmaceutical care). To pharma- much has been written and discussed in the pharmacy pro- ceutical care, however, the pharmacist contributes unique fession, especially since the publication of a paper by Hepler knowledge and skills to ensure optimal outcomes from the and Strand in 1990.3–5 ASHP has formally endorsed the con- use of medications. cept.6 With varying terminology and nuances, the concept At the heart of any type of patient care, there exists a has also been acknowledged by other national pharmacy or- one-to-one relationship between a caregiver and a patient.
    [Show full text]
  • About Skaggs School of Pharmacy & Pharmaceutical Sciences
    SOP-3363 Skaggs SOP Printed Brochure 8.5"w x 11"h 4/4 CMYK jk Content __________ Design __________ Mktg __________ Skaggs School of Pharmacy and Pharmaceutical Sciences Where Discoveries Are DeliveredSM pharmacy.ucsd.edu SOP-3363 Skaggs SOP Printed Brochure 8.5"w x 11"h 4/4 CMYK jk Content __________ Design __________ Mktg __________ About Skaggs School of Pharmacy and Pharmaceutical Sciences Offering renowned health sciences professional education, innovative clinical practice and extensive research opportunities. Our students have an average on-time graduation rate Leadership of more than 98 percent for the four-year PharmD program and an average of 99 percent NAPLEX pass > Dean, Skaggs School of Pharmacy James McKerrow, MD, PhD rates for first time exam-takers over the last five years. We also rank among leading pharmacy schools in our > Associate Dean for Admissions and Outreach research endeavors and grant funding. Rabia Atayee, PharmD, BCPS > Associate Dean for Assessment and Accreditation Collaborations Across Campus Kelly Lee, PharmD, MAS, BCPP and Around the Region > Associate Dean for Business Administration and Fiscal Affairs > School of Medicine Andrina Marshall, MA/MBA > Department of Chemistry & Biochemistry and > Associate Dean for Experiential Education Division of Biological Sciences James Colbert, PharmD > > Department of Computer Science and Engineering Associate Dean for Pharmacy Education Brookie Best, PharmD, MAS > UC San Diego Health > Associate Dean for Professional Practice Charles Daniels, BS Pharm, PhD > La Jolla
    [Show full text]
  • Successful Implementation of Pharmaceutical Care in Daily Practice
    Successful implementation of Pharmaceutical care in daily practice Charlotte Rossing, MSc pharm, PhD Director of Research and Professional Development Pharmakon, Danish College of Pharmacy Practice Vice-chair FIP SIG Pharmacy Practice Research @CharRossing @Charlotte Rossing © Pharmakon Pharmaceutical care Hepler & Strand 1990 1995 2000 2005 2010 2015 FIP community pharmacy section CPD Implemen- Pharmaceutical care for tation PCNE-funded the elderly Topics Pharmaceutical Care Self-management Patient satisfaction/health Academy Network Europe Good pharmacy practice Health economics master class FIP Tokyo 1993 (research) Patient effects Designing interventions “Pharmaceutical Guidelines and manuals Barriers and facilitators care in From evidence to practice Individualised interventions community Change management Implementation of new practice practice” PCNE working implementations Change management conferences Remuneration for Indicators to measure progress Every second year community pharmacy Theory and practice services Building capacity for change © Pharmakon © Pharmakon 1 Compliance Medication review technologies Clinical pharmacy Safe and effective use of in residential Counselling Dose dispensing medicines facilities at the 2004 pharmacy 2015 - and homecare Self- PCNE Municipality PCNE management Better use of Asthma TOM pharmacy OMA project medicines in project nursing homes collaboration 1990 1995 2000 2005 2010 2015 © Pharmakon Compliance Medication review technologies Clinical pharmacy Safe and effective use of in residential
    [Show full text]
  • LECTURE NOTES on BP 703T. PHARMACY PRACTICE
    LECTURE NOTES on BP 703T. PHARMACY PRACTICE (Theory) Unit IV a) BUDGET PREPARATION AND IMPLEMENTATION Budget preparation and its implementation are one of the important tasks of the pharmacy department of any hospital. It requires several factors into consideration like planning & strategy for maintenance and development etc. The word budget means the financial plan of a hospital for the period of a year. Budget is a quantity of plan of action and aid to the coordination and implementation of plan. DEFINITION:- Budget is described as an instrument through which hospital administration, management at the department levels and the governing bodies can review the hospital services in relationship to the prepared plan in a comprehensive and integrated form expressed in financial terms. OBJECTIVES: a) Development of standards b) Comparison of actual results with standards c) Identification of deviation or fluctuation d) Analysis of deviation e) The responsible person will use the budget f) Details to determine whether the proposal is economically feasible and realistic. g) To monitor the hospital financial activities. h) Estimate the cost of completing objectives identified in the proposal. ADVANTAGES OF PLANNING THE BUDGET: a) Develop better financial planning. b) Gives a better focus on decision making to the management. c) Effectively manage the financial aspects of the hospital d) Exposes the reasons of over expenditure e) Helps to focus on hospital priorities f) Enhance efficiency of staffs and others TYPES OF BUDGET PREPARATION: Based on the duration of budget, it can be divided in to: Short term budget (2 years) Long term budget (5 - 10 years) DIVISION OF BUDGETS: 1.
    [Show full text]
  • Implementation of Clinical Services at Various Institutions
    OBJECTIVES Implementation of • Describe various hospital pharmacy Clinical Services at quality improvement initiatives • List components of the framework Various Institutions necessary for expanding clinical services • Describe methods of utilizing pharmacist- Niki Carver, Pharm.D., UAMS Medical Center extenders in providing clinical services Shannon Hays, Pharm.D., White Co Medical • Discuss the development and Melanie Claborn, Pharm.D., Veterans implementation of clinical pharmacy Healthcare System of the Ozarks/UAMS NW services in primary care at a federal facility Disclosure This presenter has no conflicts of interest to Increasing Possibilities for Health- disclose. Systems Pharmacists Involvement Niki Carver, Pharm.D. Assistant Director for Medication Safety University of Arkansas for Medical Sciences 4 Objectives Definitions • Describe various hospital pharmacy ASHP – American Society of Health-System quality improvement initiatives Pharmacists CMS – Center of Medicare & Medicaid Services 1 Health-Systems Pharmacists’ ASHP 2015 INITIATIVE Possibilities • This Initiative is a program to help make medication use in health systems more effective, Readmissions scientific, and safe. There are six key goals and 31 specific objectives to be accomplished by the year 2015. NPSG, Core • The 2015 Initiative is a tool to help health- Measures system pharmacy practitioners achieve the ideals identified in the vision statement. Pharmacokinetic Dosing, • ASHP dedicates itself to achieving a vision for Therapeutic Drug Monitoring, pharmacy practice
    [Show full text]
  • Clinical Pharmacist Fellowship in Drug Information
    CLINICAL PHARMACIST FELLOWSHIP IN DRUG INFORMATION 2021–2023 PROGRAM BROCHURE PURPOSE The two-year post-doctoral Clinical Pharmacist Fellowship in Drug On behalf of Belmont University College of Information is designed to provide fellows with an intensive program focused in drug information, evidence-based practice, toxicology, Pharmacy and Aegis Sciences Corporation, teaching and research. It is the goal of the program to equip fellows we would like to thank prospective fellows for to serve as clinical pharmacists in a toxicology setting, university or their interest in our program. college faculty, drug information specialists, medical science liaisons or medical writers. Christy Houston Foundation Drug Information Center OBJECTIVES AND RESPONSIBILITIES BELMONT AEGIS Belmont University consists of approximately 8,400 students from Founded in 1990, Aegis Sciences Corporation is a laboratory sciences across the United States and abroad. Committed to being a leader among company specializing in healthcare services that provide science-driven teaching universities, Belmont brings together the best of liberal arts testing and consulting for clients, such as professional and amateur sports and professional education in a Christian community of learning and organizations, leading college and university athletic programs, healthcare service. The purpose of the academic portion of the fellowship program professionals, Fortune 500 companies, and government agencies is to provide fellows with exposure to academia as well as the functions throughout the United States. The Aegis experiences will be designed and responsibilities of an academic-based drug information practice. and structured to fully integrate the fellows into the daily functions and The academia experience includes providing didactic and experiential responsibilities of the Clinical Pharmacist team.
    [Show full text]
  • Shining a Spotlight on VA Clinical Pharmacy Practice: Advanced Services, Strong Communication, Quality Outcomes
    2013 Midyear Clinical Meeting Federal Forum: Challenges and Best Practice Solutions from Federal Pharmacy Objectives . Describe VA Advanced Pharmacy Services Shining a Spotlight on VA Clinical Pharmacy Practice: Advanced Services, Strong Communication, Quality Outcomes . Describe Communication Process: Education and Committee Structure Scott E. Mambourg, PharmD, BCPS, AAHIVP Representing: . Define Quality Outcomes VA Clinical Pharmacy Advisory Board (CPAB); VA Clinical Pharmacy Program Office (CPPO) Scope of Practice (SOP) . VHA Policy System‐wide since 1995 . Each VHA pharmacist with direct patient care responsibility which includes prescriptive authority must have a Scope of Advanced Practice Practice . Medication prescribing privileges for non‐controlled substances can be granted to Clinical Pharmacy Specialists (CPS) based on a locally‐defined Scope of Practice . The Scope of Practice delineates any prescriptive authority and the ability to order laboratory tests, screenings, referrals, and other items pertinent to monitoring and assessing the patient’s drug therapy. Direct Patient Care Activities Pharmacist Scope of Practice . Allows for autonomous practice and prescribing of the pharmacist to address the medication management needs of the Veterans . Prescriptive authority and responsibility will include practice areas for which the pharmacist has experience and expertise, including but not limited to: • Addressing medication management needs of patients with defined diagnoses, • Management of medication‐related adverse events, • Ongoing and acute medication monitoring, and • Collaboration with other healthcare providers for management of new diagnoses 6 © 2013 American Society of Health-System Pharmacists 1 2013 Midyear Clinical Meeting Federal Forum: Challenges and Best Practice Solutions from Federal Pharmacy Scope of Practice Core Elements of a Pharmacist Scope of Practice . Part 1.
    [Show full text]
  • Patient Case # 1
    Updates in Therapeutics® 2012: The Pharmacotherapy Preparatory Review and Recertification Course Conflict of Interest Disclosures Melody Ryan –no conflicts of interest to disclose Updates in Therapeutics® 2012: The Pharmacotherapy Preparatory Review & Recertification Course Neurology Melody Ryan, PharmD, MPH University of Kentucky College of Pharmacy Learning Objectives Patient Case # 1 Differentiate between various antiepileptic drugs based on use and adverse effects TM is an 18-year-old new patient in the Develop a treatment strategy for status epilepticus pharmacy where you work. He presents a Identify appropriate treatment strategies for primary and secondary prescription for carbamazepine 100 mg 1 PO stroke prevention BID with instructions to increase to 200 mg 1 Determine the appropriateness of treatment with tissue plasminogen activator for acute stroke PO TID. Currently, he does not take any Examine common adverse effects associated with treatment of medications and does not have any drug Parkinson disease allergies. During your counseling session, TM Differentiate between regimens for acute and prophylactice treatment tells you he must have blood drawn for a test in of migraine, tension, and cluster headaches 3 weeks. Identify common adverse effects of disease-modifying therapies for multiple sclerosis Page Number 1-326 Page Number 1-344 Patient Case # 1 Carbamazepine Adverse Effects Which of the following common potential adverse effects of carbamazepine is best assessed through a blood draw? Rash SIADH A. Leukopenia Aplastic anemia B. Renal failure Throm bocy topen ia Anemia C. Congestive heart failure Leukopenia D. Hypercalcemia Handout Page 1-344; Answer Page 1-371 Page Number 1-330 © 2012 American College of Clinical Pharmacy 1 Updates in Therapeutics® 2012: The Pharmacotherapy Preparatory Review and Recertification Course Patient Case # 2 Patient Case # 2 Which one of the following choices should be your response? A.
    [Show full text]